

Jose Lutzky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6942624/publications.pdf>

Version: 2024-02-01

72
papers

19,740
citations

126708

33
h-index

110170

64
g-index

74
all docs

74
docs citations

74
times ranked

23503
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. , 2022, 10, e004839.		4
2	A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).. Journal of Clinical Oncology, 2022, 40, TPS9593-TPS9593.	0.8	0
3	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of Clinical Oncology, 2021, 39, 2656-2666.	0.8	145
4	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. Journal of Clinical Oncology, 2021, 39, 3829-3838.	0.8	44
5	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Journal of Clinical Oncology, 2021, 39, 2647-2655.	0.8	94
6	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
7	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6
8	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer, 2020, 126, 523-530.	2.0	43
9	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. JAMA Oncology, 2020, 6, 1256.	3.4	38
10	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications, 2020, 11, 6262.	5.8	50
11	P865â€¦Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies â€“ independent review committee data update. , 2020, , .		3
12	Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.. Journal of Clinical Oncology, 2020, 38, 10004-10004.	0.8	19
13	Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.. Journal of Clinical Oncology, 2020, 38, 10006-10006.	0.8	32
14	Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma.. Journal of Clinical Oncology, 2020, 38, 10017-10017.	0.8	6
15	Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNÎ² and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.. Journal of Clinical Oncology, 2020, 38, TPS3161-TPS3161.	0.8	1
16	Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e448-e458.	2.2	168
17	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2019, 6, e459-e469.	2.2	174
18	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 1794-1806.	0.5	69

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. <i>Cancer</i> , 2019, 125, 1113-1123.	2.0	45
20	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
21	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	0.8	6
22	A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2648-TPS2648.	0.8	5
23	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144,) Tj ETQq1 1 0.784314 rgBT /Overlock systemic therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 136-136.	0.8	2
24	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9592-9592.	0.8	4
25	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIBâ€“IVMÎc melanoma. <i>Melanoma Research</i> , 2018, 28, 44-51.	0.6	31
26	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018, 23, 193-202.	1.9	60
27	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
28	Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4032-4032.	0.8	4
29	A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9595-TPS9595.	0.8	2
30	Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 169-169.	0.8	5
31	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 439-445.	1.2	10
32	Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. <i>Supportive Care in Cancer</i> , 2017, 25, 3217-3224.	1.0	2
33	Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. , 2017, 5, 3.		44
34	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	0.9	31
35	Rindopemimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
36	A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 109-109.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 3007-3007.	0.8	15
38	Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.. Journal of Clinical Oncology, 2017, 35, 9085-9085.	0.8	7
39	Dynamics of tumor response in advanced melanoma patients treated with Cocksackievirus A21.. Journal of Clinical Oncology, 2016, 34, 9553-9553.	0.8	2
40	Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, e21041-e21041.	0.8	4
41	Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. Cancer Management and Research, 2015, 7, 47.	0.9	29
42	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research, 2015, 21, 2289-2296.	3.2	128
43	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 3003-3003.	0.8	120
44	Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8032-8032.	0.8	97
45	Final data from CALM: A phase II study of Cocksackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 9030-9030.	0.8	44
46	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. JAMA - Journal of the American Medical Association, 2014, 311, 2397.	3.8	359
47	Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205. Science Translational Medicine, 2014, 6, 232ra51.	5.8	315
48	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma. Chinese Clinical Oncology, 2014, 3, 30.	0.4	6
49	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews Clinical Oncology, 2013, 10, 588-598.	12.5	177
50	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. Clinical Cancer Research, 2011, 17, 7462-7469.	3.2	100
51	KIT as a Therapeutic Target in Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2011, 305, 2327.	3.8	755
52	Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma. Clinical Cancer Research, 2010, 16, 2402-2408.	3.2	66
53	Velimogene aliplasmid. Expert Opinion on Biological Therapy, 2010, 10, 841-851.	1.4	4
54	New Therapeutic Options in the Medical Management of Advanced Melanoma. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 249-257.	1.6	14

#	ARTICLE	IF	CITATIONS
55	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
56	Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. <i>Lancet Oncology</i> , The, 2010, 11, 155-164.	5.1	1,075
57	Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6207-6212.	0.8	38
58	Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2009, 146, 619-626.	1.2	58
59	Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 492-493.	1.5	213
60	Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 955-962.	0.8	238
61	Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. <i>British Journal of Haematology</i> , 2006, 135, 174-183.	1.2	74
62	A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. <i>Investigational New Drugs</i> , 2006, 24, 89-94.	1.2	8
63	Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.. <i>Blood</i> , 2006, 108, 796-796.	0.6	25
64	An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. <i>Melanoma Research</i> , 2005, 15, 283-285.	0.6	35
65	Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 776-783.	1.2	378
66	A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.. <i>Blood</i> , 2004, 104, 333-333.	0.6	16
67	Antibody-based vaccines for the treatment of melanoma. <i>Seminars in Oncology</i> , 2002, 29, 462-470.	0.8	16
68	Clinical and Immune Responses in Advanced Melanoma Patients Immunized With an Anti-Idiotypic Antibody Mimicking Disialoganglioside GD2. <i>Journal of Clinical Oncology</i> , 2000, 18, 376-376.	0.8	132
69	Collateral sensitivity to radiation and CIS-platinum in a multidrug-resistant human leukemia cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 37, 168-172.	1.1	0
70	Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. <i>Gynecologic Oncology</i> , 1992, 45, 32-39.	0.6	10
71	Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 93-101.	1.1	9
72	Nodular Bleomycin Toxicity. <i>American Journal of Clinical Pathology</i> , 1989, 92, 101-104.	0.4	40